Literature DB >> 30548198

PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p.

Mengchao Yu1, Zhijian Liu2, Yuan Liu1, Xinyan Zhou1, Feng Sun2, Yanqing Liu1, Liuyi Li1, Shiyu Hua1, Yi Zhao1, Haidong Gao1, Zhouting Zhu2, Muhan Na1, Qipeng Zhang1, Rong Yang3, Jianguo Zhang4, Yongzhong Yao2, Xi Chen1.   

Abstract

The protein tyrosine phosphatase PTP1B, which is encoded by PTPN1, is a ubiquitously expressed nonreceptor protein tyrosine phosphatase. PTP1B has long been known to negatively regulate insulin and leptin receptor signalling. Recently, it was reported to be aberrantly expressed in cancer cells and to function as an important oncogene. In this study, we found that PTP1B protein levels are dramatically increased in breast cancer (BC) tissues and that PTP1B promotes the proliferation, and suppresses the apoptosis, of both HER2-positive and triple-negative BC cell lines. Bioinformatics analysis identified that the miRNA, miR-193a-3p, might potentially target PTP1B. We demonstrate that miR-193a-3p regulates PTP1B in BC cells and that it regulates the proliferation and apoptosis of BC cells by targeting PTP1B, both in vitro and in vivo. In conclusion, this study confirms that PTP1B acts as an oncogene in BC and demonstrates that miR-193a-3p can serve as a tumour suppressor gene in BC by targeting PTP1B.
© 2018 Federation of European Biochemical Societies.

Entities:  

Keywords:  PTP1B; apoptosis; breast cancer; miR-193a-3p; proliferation

Year:  2018        PMID: 30548198     DOI: 10.1111/febs.14724

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  17 in total

1.  Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis.

Authors:  Shoubin Zhan; Ping Yang; Shengkai Zhou; Ye Xu; Rui Xu; Gaoli Liang; Chenyu Zhang; Xi Chen; Liuqing Yang; Fangfang Jin; Yanbo Wang
Journal:  Front Med       Date:  2022-04-13       Impact factor: 4.592

Review 2.  Human Protein Tyrosine Phosphatase 1B (PTP1B): From Structure to Clinical Inhibitor Perspectives.

Authors:  Rongxing Liu; Cécile Mathieu; Jérémy Berthelet; Wenchao Zhang; Jean-Marie Dupret; Fernando Rodrigues Lima
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

3.  Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.

Authors:  Xiao-Jiao Li; Rong Wen; Dong-Yue Wen; Peng Lin; Deng-Hua Pan; Li-Jie Zhang; Yu He; Lin Shi; Yong-Ying Qin; Yun-Hui Lai; Jing-Ni Lai; Jun-Lin Yang; Qin-Qiao Lai; Jun Wang; Jun Ma; Hong Yang; Yu-Yan Pang
Journal:  Mol Med Rep       Date:  2020-07-08       Impact factor: 2.952

4.  Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p.

Authors:  Zaiyu Li; Cong Hu; Yu Zhen; Bo Pang; Huanfa Yi; Xianglin Chen
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

5.  Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.

Authors:  Xiangxun Chen; Mengxi Zhou; Wenjie Fan; Mingwei Yang; Lin Yang
Journal:  Drug Des Devel Ther       Date:  2021-01-13       Impact factor: 4.162

6.  Transcriptome-wide analysis reveals insight into tumor suppressor functions of 1B3, a novel synthetic miR-193a-3p mimic.

Authors:  Marion T J van den Bosch; Sanaz Yahyanejad; Mir Farshid Alemdehy; Bryony J Telford; Thijs de Gunst; Harm C den Boer; Rogier M Vos; Marieke Stegink; Laurens A H van Pinxteren; Roel Q J Schaapveld; Michel Janicot
Journal:  Mol Ther Nucleic Acids       Date:  2021-01-26       Impact factor: 8.886

7.  Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology.

Authors:  Bryony J Telford; Sanaz Yahyanejad; Thijs de Gunst; Harm C den Boer; Rogier M Vos; Marieke Stegink; Marion T J van den Bosch; Mir Farshid Alemdehy; Laurens A H van Pinxteren; Roel Q J Schaapveld; Michel Janicot
Journal:  Oncotarget       Date:  2021-03-02

8.  Docosahexaenoic Acid Inhibits PTP1B Phosphatase and the Viability of MCF-7 Breast Cancer Cells.

Authors:  Alicja Kuban-Jankowska; Magdalena Gorska-Ponikowska; Kamlesh Kumar Sahu; Tomasz Kostrzewa; Michal Wozniak; Jack Tuszynski
Journal:  Nutrients       Date:  2019-10-23       Impact factor: 5.717

9.  Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy.

Authors:  Lingling Yang; Feng Chen; Cheng Gao; Jiabao Chen; Junyan Li; Siyan Liu; Yuanyuan Zhang; Zhouyu Wang; Shan Qian
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

10.  Identification of the anti-breast cancer targets of triterpenoids in Liquidambaris Fructus and the hints for its traditional applications.

Authors:  Ping Qian; Xiao-Ting Mu; Bing Su; Lu Gao; Dong-Fang Zhang
Journal:  BMC Complement Med Ther       Date:  2020-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.